JDRF announces ProSciento as the first ever California wide sponsor of the Northern California and Southern California One Walks. ProSciento, a leading clinical research organization headquartered in Chula Vista, California, has been a longtime JDRF supporter. Since 2007, they have participated in the JDRF San Diego Gala, TypeOneNation Summit, and the One Walk, contributing over $100,000 from fundraising and sponsorship to support type 1 diabetes (T1D) research.
“ProSciento is delighted to announce our California-wide partnership with JDRF and this expanded opportunity to share our core values of making a positive difference in the lives of patients with metabolic diseases through meaningful clinical research and partnerships with patient advocacy groups . We want to thank JDRF for the tremendously impactful work that they are doing on behalf of the T1D and overall diabetes community, locally, regionally and ultimately, across the country and the globe,” commented Dr. Marcus Hompesch, ProSciento’s Chairman and Chief Executive Officer.
Each year, the JDRF One Walks in Northern and Southern California bring together over 10,000 walkers to change the future of T1D. Many of these walkers have T1D themselves, and many more are friends, family, or coworkers of someone challenged by this disease and who walk with the common goal of better treating, preventing, and ultimately curing T1D, a life-threatening disease that affects over 1.6 million Americans.
This year, the Northern and Southern California One Walks will take place virtually on Sunday, November 7. It is an opportunity for JDRF walkers throughout California to gather with their family and friends to celebrate their loved one(s) living with T1D and the fundraising efforts that they have made to accelerate T1D research.
To join JDRF and ProSciento for a One Walk in Northern or Southern California, please click on the Walk closest to your location:
About ProSciento, Inc.
ProSciento is a metabolism-focused, full scope clinical R&D services provider, with a mission to advance the global development of novel therapeutics for type 1 and type 2 diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all metabolic drug and device classes. Utilizing its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, an unparalleled methodological tool kit, and operational execution from late preclinical to phase III readiness – ProSciento provides highly customizable services for its global client base in today’s rapidly evolving landscape of metabolic drug and device development. For more information, please visit www.prosciento.com.
Learn more about ProSciento’s type 1 diabetes studies here.